REG1V Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for REG1V from our risk checks.
Revenio Group Oyj Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €33.80 |
52 Week High | €33.98 |
52 Week Low | €17.51 |
Beta | 1.34 |
11 Month Change | 19.35% |
3 Month Change | 21.23% |
1 Year Change | 42.74% |
33 Year Change | -47.68% |
5 Year Change | 73.69% |
Change since IPO | 1,678.99% |
Recent News & Updates
Investors Shouldn't Overlook Revenio Group Oyj's (HEL:REG1V) Impressive Returns On Capital
Aug 11Calculating The Intrinsic Value Of Revenio Group Oyj (HEL:REG1V)
Jun 20What Does Revenio Group Oyj's (HEL:REG1V) Share Price Indicate?
May 21Revenio Group Oyj Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 27Recent updates
Investors Shouldn't Overlook Revenio Group Oyj's (HEL:REG1V) Impressive Returns On Capital
Aug 11Calculating The Intrinsic Value Of Revenio Group Oyj (HEL:REG1V)
Jun 20What Does Revenio Group Oyj's (HEL:REG1V) Share Price Indicate?
May 21Revenio Group Oyj Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 27It's Unlikely That The CEO Of Revenio Group Oyj (HEL:REG1V) Will See A Huge Pay Rise This Year
Mar 29€27.88 - That's What Analysts Think Revenio Group Oyj (HEL:REG1V) Is Worth After These Results
Feb 18Is Revenio Group Oyj (HEL:REG1V) Using Too Much Debt?
Feb 16Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching
Dec 15Revenio Group Oyj (HEL:REG1V) Seems To Use Debt Rather Sparingly
Aug 03Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?
Jun 13If EPS Growth Is Important To You, Revenio Group Oyj (HEL:REG1V) Presents An Opportunity
May 09Revenio Group Oyj (HEL:REG1V) Has A Rock Solid Balance Sheet
Apr 11A Look At The Fair Value Of Revenio Group Oyj (HEL:REG1V)
Mar 30If EPS Growth Is Important To You, Revenio Group Oyj (HEL:REG1V) Presents An Opportunity
Feb 08Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching
Jan 26Revenio Group Oyj (HEL:REG1V) Has A Rock Solid Balance Sheet
Jan 06Is Revenio Group Oyj (HEL:REG1V) Worth €39.4 Based On Its Intrinsic Value?
Dec 09Is Revenio Group Oyj (HEL:REG1V) Using Too Much Debt?
Oct 06Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?
Sep 17A Look At The Fair Value Of Revenio Group Oyj (HEL:REG1V)
Aug 20Does Revenio Group Oyj (HEL:REG1V) Have A Healthy Balance Sheet?
Jun 14Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching
Jun 01A Look At The Intrinsic Value Of Revenio Group Oyj (HEL:REG1V)
May 18Here's Why I Think Revenio Group Oyj (HEL:REG1V) Is An Interesting Stock
Mar 27Revenio Group Oyj (HEL:REG1V) Has A Rock Solid Balance Sheet
Mar 14Calculating The Fair Value Of Revenio Group Oyj (HEL:REG1V)
Feb 16Should You Think About Buying Revenio Group Oyj (HEL:REG1V) Now?
Feb 03Revenio Group Oyj (HEL:REG1V) Will Want To Turn Around Its Return Trends
Jan 23Does Revenio Group Oyj (HEL:REG1V) Have A Healthy Balance Sheet?
Dec 12A Look At The Fair Value Of Revenio Group Oyj (HEL:REG1V)
Nov 01Here's Why I Think Revenio Group Oyj (HEL:REG1V) Is An Interesting Stock
Oct 13Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?
Sep 12The Returns On Capital At Revenio Group Oyj (HEL:REG1V) Don't Inspire Confidence
Aug 30If You Like EPS Growth Then Check Out Revenio Group Oyj (HEL:REG1V) Before It's Too Late
Jul 13Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?
Jun 07Earnings Update: Revenio Group Oyj Beat Earnings And Now Analysts Have New Forecasts For This Year
Apr 26Here's Why We Think Revenio Group Oyj (HEL:REG1V) Is Well Worth Watching
Mar 14Statutory Profit Doesn't Reflect How Good Revenio Group Oyj's (HEL:REG1V) Earnings Are
Feb 22Shareholder Returns
REG1V | FI Medical Equipment | FI Market | |
---|---|---|---|
7D | 4.3% | 4.3% | 1.5% |
1Y | 42.7% | 32.2% | -3.1% |
Return vs Industry: REG1V exceeded the Finnish Medical Equipment industry which returned 32.2% over the past year.
Return vs Market: REG1V exceeded the Finnish Market which returned -3.1% over the past year.
Price Volatility
REG1V volatility | |
---|---|
REG1V Average Weekly Movement | 4.0% |
Medical Equipment Industry Average Movement | 5.8% |
Market Average Movement | 4.4% |
10% most volatile stocks in FI Market | 7.4% |
10% least volatile stocks in FI Market | 2.6% |
Stable Share Price: REG1V has not had significant price volatility in the past 3 months.
Volatility Over Time: REG1V's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 229 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
REG1V fundamental statistics | |
---|---|
Market cap | €898.94m |
Earnings (TTM) | €19.31m |
Revenue (TTM) | €100.49m |
46.6x
P/E Ratio8.9x
P/S RatioIs REG1V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REG1V income statement (TTM) | |
---|---|
Revenue | €100.49m |
Cost of Revenue | €29.34m |
Gross Profit | €71.14m |
Other Expenses | €51.84m |
Earnings | €19.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
Earnings per share (EPS) | 0.73 |
Gross Margin | 70.80% |
Net Profit Margin | 19.22% |
Debt/Equity Ratio | 13.2% |
How did REG1V perform over the long term?
See historical performance and comparison